Alethea Capital Management’s Kura Oncology KURA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $23.8M | Buy |
2,167,938
+638,569
| +42% | +$6.02M | 9.85% | 3 |
|
|
2026
Q1 | $12.4M | Buy |
1,529,369
+106,687
| +7% | +$917K | 6.38% | 3 |
|
|
2025
Q4 | $14.8M | Buy |
1,422,682
+33,888
| +2% | +$356K | 7.18% | 4 |
|
|
2025
Q3 | $12.3M | Buy |
1,388,794
+439,509
| +46% | +$3.13M | 7.9% | 4 |
|
|
2025
Q2 | $5.48M | Buy |
949,285
+290,108
| +44% | +$1.78M | 4.15% | 5 |
|
|
2025
Q1 | $4.35M | Buy |
659,177
+100,735
| +18% | +$785K | 3.25% | 5 |
|
|
2024
Q4 | $4.86M | Buy |
558,442
+4,900
| +0.9% | +$70.5K | 4.16% | 4 |
|
|
2024
Q3 | $10.8M | Buy |
553,542
+287,636
| +108% | +$5.83M | 7.81% | 4 |
|
|
2024
Q2 | $5.48M | Buy |
265,906
+6,300
| +2% | +$130K | 4.15% | 4 |
|
|
2024
Q1 | $5.54M | Sell |
259,606
-90,839
| -26% | -$1.77M | 4.5% | 4 |
|
|
2023
Q4 | $5.04M | Hold |
350,445
| – | – | 5.81% | 3 |
|
|
2023
Q3 | $3.2M | Buy |
350,445
+17,000
| +5% | +$173K | 3.93% | 3 |
|
|
2023
Q2 | $3.53M | Sell |
333,445
-30,328
| -8% | -$359K | 3.77% | 3 |
|
|
2023
Q1 | $4.45M | Hold |
363,773
| – | – | 4.7% | 3 |
|
|
2022
Q4 | $4.51M | Sell |
363,773
-2,796
| -0.8% | -$40.6K | 4.33% | 4 |
|
|
2022
Q3 | $5.01M | Hold |
366,569
| – | – | 6.33% | 4 |
|
|
2022
Q2 | $6.72M | Buy |
366,569
+8,949
| +3% | +$129K | 8.41% | 3 |
|
|
2022
Q1 | $5.75M | Buy |
357,620
+271,820
| +317% | +$3.93M | 5.2% | 4 |
|
|
2021
Q4 | $1.2M | Buy |
+85,800
| New | +$1.39M | 1.02% | 7 |
|
|
2021
Q1 | – | Sell |
-67,568
| Closed | -$2.21M | – | 98 |
|
|
2020
Q4 | $2.21M | Sell |
67,568
-48,073
| -42% | -$1.69M | 1.11% | 8 |
|
|
2020
Q3 | $3.54M | Sell |
115,641
-100,530
| -47% | -$2.22M | 2.4% | 5 |
|
|
2020
Q2 | $3.52M | Sell |
216,171
-102,821
| -32% | -$1.48M | 2.06% | 6 |
|
|
2020
Q1 | $3.17M | Buy |
318,992
+52,465
| +20% | +$601K | 2.06% | 4 |
|
|
2019
Q4 | $3.67M | Hold |
266,527
| – | – | 1.57% | 4 |
|
|
2019
Q3 | $4.04M | Hold |
266,527
| – | – | 2.56% | 4 |
|
|
2019
Q2 | $5.25M | Buy |
266,527
+27,611
| +12% | +$458K | 3.42% | 4 |
|
|
2019
Q1 | $3.96M | Buy |
238,916
+21,166
| +10% | +$326K | 2.82% | 4 |
|
|
2018
Q4 | $3.06M | Buy |
217,750
+2,088
| +1% | +$27.7K | 4.45% | 3 |
|
|
2018
Q3 | $3.77M | Hold |
215,662
| – | – | 5.66% | 2 |
|
|
2018
Q2 | $3.92M | Buy |
215,662
+35,067
| +19% | +$594K | 6.7% | 2 |
|
|
2018
Q1 | $3.39M | Buy |
180,595
+90,922
| +101% | +$1.77M | 4.59% | 2 |
|
|
2017
Q4 | $1.37M | Sell |
89,673
-22,000
| -20% | -$324K | 2.18% | 4 |
|
|
2017
Q3 | $1.67M | Buy |
111,673
+15,000
| +16% | +$141K | 1.96% | 20 |
|
|
2017
Q2 | $899K | Buy |
96,673
+11,904
| +14% | +$108K | 1.02% | 31 |
|
|
2017
Q1 | $746K | Buy |
84,769
+20,469
| +32% | +$150K | 0.9% | 33 |
|
|
2016
Q4 | $379K | Hold |
64,300
| – | – | 0.48% | 55 |
|
|
2016
Q3 | $402K | Buy |
64,300
+2,300
| +4% | +$11.7K | 0.56% | 48 |
|
|
2016
Q2 | $168K | Buy |
+62,000
| New | +$193K | 0.23% | 57 |
|
Other funds holding KURA
SCM
BI
AC
PM
Alethea Capital Management's KURA Position: Q2 2026 in Review
Alethea Capital Management increased its Kura Oncology (KURA) stake by 42% in Q2 2026, buying an estimated $6.02M and bringing the position to 2,167,938 shares worth $23.8M. The position accounts for 9.85% of the portfolio, ranked #3.
Alethea Capital Management first reported a position in KURA in Q2 2016 and has held it in 38 quarters since. 220 funds tracked by Wall St. Rank hold KURA as of Q2 2026.
- Alethea Capital Management held 2,167,938 shares of Kura Oncology worth $23.8M as of Q2 2026.
- Alethea Capital Management bought 638,569 Kura Oncology shares in Q2 2026, an estimated $6.02M.
- Kura Oncology made up 9.85% of Alethea Capital Management's portfolio in Q2 2026, its #3 holding.
- Alethea Capital Management first reported a position in Kura Oncology in Q2 2016 and has held it in 38 quarters since.
- 220 funds tracked by Wall St. Rank held Kura Oncology as of Q2 2026.
Based on Alethea Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.